Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Study of GDC-9545 Alone or in Combination With Palbociclib and / or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Breast
Breast
This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and / or luteinizing hormone?releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.
Breast
I
Mayer, Ingrid
NCT03332797
VICCBREP1786